Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Recruiting Phase 3 Interventional Accepts healthy volunteers

A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age

ClinicalTrials.gov ID: NCT06693895

Public ClinicalTrials.gov record NCT06693895. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jun 25, 2026, 12:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3a, Observer-blind, Randomized, Controlled Study to Evaluate the Safety of an Investigational Varicella Vaccine Compared With Varivax, Administered as a First Dose to Healthy Children 12 to 15 Months of Age

Study identification

NCT ID
NCT06693895
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
750 participants

Conditions and interventions

Conditions

Interventions

  • Investigational varicella vaccine Biological
  • Marketed varicella vaccine Biological
  • Measles, mumps, and rubella vaccine Biological
  • Hepatitis A vaccine Biological
  • PCV (pneumococcal conjugate vaccine) 13 Biological
  • PCV 20 Biological
  • Vaxneuvance Biological

Biological

Eligibility (public fields only)

Age range
12 Months to 15 Months
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 25, 2024
Primary completion
Nov 22, 2026
Completion
Nov 22, 2026
Last update posted
May 28, 2026

2024 – 2026

United States locations

U.S. sites
22
U.S. states
12
U.S. cities
21
Facility City State ZIP Site status
GSK Investigational Site Phoenix Arizona 85006 Withdrawn
GSK Investigational Site Tucson Arizona 85741 Withdrawn
GSK Investigational Site Huntington Park California 90057 Recruiting
GSK Investigational Site National City California 91950 Recruiting
GSK Investigational Site West Covina California 91790 Recruiting
GSK Investigational Site Hialeah Florida 33012 Recruiting
GSK Investigational Site Miami Florida 33142 Recruiting
GSK Investigational Site Chicago Illinois 60621 Recruiting
GSK Investigational Site El Dorado Kansas 67042 Withdrawn
GSK Investigational Site Lafayette Louisiana 70508 Recruiting
GSK Investigational Site Mankato Minnesota 56002 Recruiting
GSK Investigational Site Lincoln Nebraska 68516 Recruiting
GSK Investigational Site Cincinnati Ohio 45245 Recruiting
GSK Investigational Site Dallas Texas 75230-2571 Recruiting
GSK Investigational Site Dallas Texas 75235 Withdrawn
GSK Investigational Site Houston Texas 77065 Recruiting
GSK Investigational Site Richmond Texas 77469 Recruiting
GSK Investigational Site San Antonio Texas 78244 Withdrawn
GSK Investigational Site Roy Utah 84067 Completed
GSK Investigational Site Syracuse Utah 84075 Recruiting
GSK Investigational Site Richmond Virginia 23294 Recruiting
GSK Investigational Site Vienna Virginia 22180 Withdrawn

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 22 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06693895, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 28, 2026 · Synced Jun 25, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06693895 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →